mergers & acquisitions

JPK provides microscopy instrumentation for biomolecular and cellular imaging, as well as force measurements on single molecules, cells, and tissues.

The deal gives Biodesix an additional test in the lung cancer space, Indi's XL2, which helps to classify lung nodules identified by imaging scans as benign or malignant.

Natera led the Index with a 61 percent increase in stock price, driven by the firm's announcement that it was entering the transplantation market.

Through the deal, Precision Therapeutics will acquire the 75 percent stake in Helomics that it does not already own.

Bio-Techne will pay $250 million in cash, as well as up to an additional $325 million contingent on the achievement of certain milestones.

Under a definitive merger agreement, Roche will acquire outstanding shares of Foundation's common stock for $137 per share.

With its purchase of decision support technology maker Interactive Biosoftware, Sophia looks to extend its AI platform deeper into NGS interpretation.

The merger, which was previously scuttled and later revived with Rosetta shareholder approval, was due to close on May 27.

The $375 million deal marks the integration of Myriad, a leader in the hereditary cancer genetic screening market, with Counsyl, a leader in reproductive genetic screening.

Myriad will merge Counsyl’s reproductive tests with its preventive care business unit into a new business unit called Myriad Women’s Health.

Pages

In a commentary at eLife, Brandeis University's Eve Marder calls on researchers to value and pursue truth.

Researchers have developed a way to quickly edit white blood cells, according to the New York Times.

In Science this week: rice gene enables plants to grow quickly in times of flooding, and more.

Education-linked genetic variants could also predict a small portion of a person's social mobility, Newsweek reports.